Reduced-Dose Fibrinolytic Acceleration of ST-Segment Elevation Myocardial Infarction Treatment Coupled With Urgent Percutaneous Coronary Intervention Compared to Primary Percutaneous Coronary Intervention Alone. Results of the AMICO (Alliance for Myocardial Infarction Care Optimization) Registry

JACC: Cardiovascular Interventions

Volumn 1, Issue 5, 2008, Pages 504-510

  Denktas, Ali E ^a   Athar, Haris ^a   Henry, Timothy D ^b   Larson, David M ^c   Simons, Michael ^d   Chan, Roger S ^d   Niles, Nathaniel W ^d   Thiele, Holger ^e   Schuler, Gerhard ^e   Ahn, Chul ^f   Sdringola, Stefano ^a   Anderson, H Vernon ^a   McKay, Raymond G ^g   Smalling, Richard W ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^b MINNEAPOLIS HEART INSTITUTE FOUNDATION   (United States)

^c Ridgeview Medical Center   (United States)

^d DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

^e UNIVERSITY OF LEIPZIG   (Germany)

^f UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^g UNIVERSITY OF CONNECTICUT SCHOOL OF MEDICINE   (United States)

Author keywords

angioplasty; fibrinolysis; meta analysis; myocardial infarction; percutaneous coronary intervention

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; FIBRINOLYTIC AGENT; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; RETEPLASE; TENECTEPLASE; TISSUE PLASMINOGEN ACTIVATOR;

ARTICLE; CLINICAL TRIAL; DEATH; DISEASE CLASSIFICATION; EMERGENCY SURGERY; FIBRINOLYSIS; HEART CATHETERIZATION; HEART INFARCTION; HEART REINFARCTION; HOSPITAL ADMISSION; HUMAN; INCIDENCE; INTERMETHOD COMPARISON; META ANALYSIS; MORTALITY; PERCUTANEOUS CORONARY INTERVENTION; PREDICTION; PRIORITY JOURNAL; ST SEGMENT ELEVATION; STROKE; SURGICAL APPROACH; SYSTEMATIC REVIEW; VASCULAR PATENCY;

AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; COMBINED MODALITY THERAPY; CORONARY CIRCULATION; EMERGENCY MEDICAL SERVICES; FEMALE; FIBRINOLYTIC AGENTS; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MYOCARDIAL INFARCTION; RECURRENCE; REGISTRIES; RISK ASSESSMENT; RISK FACTORS; STROKE; THROMBOLYTIC THERAPY; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES; VASCULAR PATENCY;

EID: 54049149931     PISSN: 19368798     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jcin.2008.06.009     Document Type: Article

References (26)

1. American Heart Association. Heart Disease and Stroke Statistics-2006 Update. http://americanheart.org/statistics Accessed December 2007
2. McNamara R.L., Herrin J., Bradley E.H., et al. Hospital improvement in time to reperfusion in patients with acute myocardial infarction, 1999 to 2002. J Am Coll Cardiol 47 (2006) 45-51
3. De Luca G., Suryapranata H., Ottervanger J.P., and Antman E.M. Time delay to treatment and mortality in primary angioplasty for acute myocardial infarction: every minute of delay counts. Circulation 109 (2004) 1223-1225
4. Brodie B.R., Hansen C., Stuckey T.D., et al. Door-to-balloon time with primary percutaneous coronary intervention for acute myocardial infarction impacts late cardiac mortality in high-risk patients and patients presenting early after the onset of symptoms. J Am Coll Cardiol 47 (2006) 289-295
5. Juliard J.M., Feldman L.J., Golmard J.L., et al. Relation of mortality of primary angioplasty during acute myocardial infarction to door-to-Thrombolysis In Myocardial Infarction (TIMI) time. Am J Cardiol 91 (2003) 1401-1405
6. McAleer B., Ruane B., Burke E., et al. Prehospital thrombolysis in a rural community: short- and long-term survival. Cardiovasc Drugs Ther 6 (1992) 369-372
7. Schofield P.M. Acute myocardial infarction: the case for pre-hospital thrombolysis with or without percutaneous coronary intervention. Heart 91 Suppl 3 (2005) iii7-iii11
8. Keeley E.C., Boura J.A., and Grines C.L. Comparison of primary and facilitated percutaneous coronary interventions for ST-elevation myocardial infarction: quantitative review of randomised trials. Lancet 367 (2006) 579-588
9. Assessment of the Safety and Efficacy of a New Treatment Strategy with Percutaneous Coronary Intervention (ASSENT-4 PCI) investigators. Primary versus tenecteplase-facilitated percutaneous coronary intervention in patients with ST-segment elevation acute myocardial infarction (ASSENT-4 PCI): randomised trial. Lancet 367 (2006) 569-578
10. Henry T.D., Unger B.T., Sharkey S.W., et al. Design of a standardized system for transfer of patients with ST-elevation myocardial infarction for percutaneous coronary intervention. Am Heart J 150 (2005) 373-384
11. Henry T.D., Sharkey S.W., Burke M.N., et al. A regional system to provide timely access to percutaneous coronary intervention for ST-elevation myocardial infarction. Circulation 116 (2007) 721-728
12. Thiele H., Engelmann L., Elsner K., et al. Comparison of pre-hospital combination-fibrinolysis plus conventional care with pre-hospital combination-fibrinolysis plus facilitated percutaneous coronary intervention in acute myocardial infarction. Eur Heart J 26 (2005) 1956-1963
13. Giesler G.M., Vooletich M., Julapalli V., et al. Coordinated aggressive medical and interventional therapy for acute myocardial infarction: Pre-hospital Administration of Thrombolysis With Urgent Culprit Artery Revascularization (PATCAR). Am J Cardiol 96 (2005) 56H
14. Smalling R.W., Giesler G.M., Julapalli V.R., et al. Pre-hospital reduced-dose fibrinolysis coupled with urgent percutaneous coronary intervention reduces time to reperfusion and improves angiographic perfusion score compared with prehospital fibrinolysis alone or primary percutaneous coronary intervention: results of the PATCAR pilot trial. J Am Coll Cardiol 50 (2007) 1612-1614
15. Boersma E., Maas A.C., Deckers J.W., and Simoons M.L. Early thrombolytic treatment in acute myocardial infarction: reappraisal of the golden hour. Lancet 348 (1996) 771-775
16. Stone G.W., Cox D., Garcia E., et al. Normal flow (TIMI-3) before mechanical reperfusion therapy is an independent determinant of survival in acute myocardial infarction: analysis from the Primary Angioplasty in Myocardial Infarction trials. Circulation 104 (2001) 636-641
17. Stringer K.A. TIMI grade flow, mortality, and the GUSTO-III trial. Pharmacotherapy 18 (1998) 699-705
18. Weaver W.D., Simes R.J., Betriu A., et al. Comparison of primary coronary angioplasty and intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review. JAMA 278 (1997) 2093-2098
19. Meijer A., Verheugt F.W., Werter C.J., Lie K.I., van der Pol J.M., and van Eenige M.J. Aspirin versus coumadin in the prevention of reocclusion and recurrent ischemia after successful thrombolysis: a prospective placebo-controlled angiographic study. Results of the APRICOT study. Circulation 87 (1993) 1524-1530
20. Brouwer M.A., Martin J.S., Maynard C., et al. Influence of early prehospital thrombolysis on mortality and event-free survival (the Myocardial Infarction Triage and Intervention [MITI] randomized trial). MITI Project Investigators. Am J Cardiol 78 (1996) 497-502
21. Ting H.H., Rihal C.S., Gersh B.J., et al. Regional systems of care to optimize timeliness of reperfusion therapy for ST-elevation myocardial infarction. The Mayo Clinic STEMI protocol. Circulation 116 (2007) 729-736
22. Ross A.M., Coyne K.S., Reiner J.S., et al., PACT Investigators. A randomized trial comparing primary angioplasty with a strategy of short-acting thrombolysis and immediate planned rescue angioplasty in acute myocardial infarction: the PACT trial. Plasminogen activator Angioplasty Compatibility Trial. J Am Coll Cardiol 34 (1999) 1954-1962
23. Van de Werf F., Armstrong P.W., Granger C., and Wallentin L. Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction. Lancet 358 (2001) 605-613
24. Desmet W., Ross A., Granger C., Armstrong P., and de Wert F.V. Tenecteplase-pretreated STEMI patients with TIMI 0-2 flow before PCI are less likely to have TIMI 3 flow after PCI (abstr). J Am Coll Cardiol 49 Suppl A (2007) 227A
25. Ellis S.G., Armstrong P., Betriu A., et al. Facilitated percutaneous coronary intervention versus primary percutaneous coronary intervention: design and rationale of the Facilitated Intervention with Enhanced Reperfusion Speed to Stop Events (FINESSE) trial. Am Heart J 147 (2004) E16
26. Ellis S., Murphy S.A., and Gibson C.M. Facilitated Intervention with Enhanced Reperfusion Speed to Stop Events (FINESSE). J Am Coll Cardiol 50 (2007) C7-C8